Lanreotide (diTFA)

Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome[1][2].

Product Specifications

CAS Number

[1024499-83-9]

Product Name Alternative

BIM 23014 (diTFA)

UNSPSC

12352209

Target

Somatostatin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/lanreotide-ditfa.html

Solubility

10 mM in DMSO

Smiles

O=C([C@@H](NC([C@@](CSSC[C@@H](C(N[C@H](C(N)=O)[C@H](O)C)=O)NC([C@H](C(C)C)NC([C@@](CCCCN)([H])NC1=O)=O)=O)([H])NC([C@H](N)CC2=CC3=CC=CC=C3C=C2)=O)=O)CC4=CC=C(O)C=C4)N[C@@H]1CC5=CNC6=C5C=CC=C6.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O

Molecular Formula

C58H71F6N11O14S2

Molecular Weight

1324.37

References & Citations

[1]Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16 (3) :1045-55.|[2]Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf) . 2003 Jul;59 (1) :115-28.